Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/1b First-In-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 Monotherapy and in Combination With Nivolumab in Subjects With Advanced Solid Tumors

NCT02637531 is registered in ClinicalTrials.gov with Infinity Pharmaceuticals, Inc. as lead sponsor.

NCT NCT02637531
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02637531 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/1b First-In-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 Monotherapy and in Combination With Nivolumab in Subjects With Advanced Solid Tumors
Lead sponsor
Infinity Pharmaceuticals, Inc.
Phase
Phase 1
Overall status
Unknown status
Start date
December 31, 2015
Completion date
December 31, 2022
Enrollment
219 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

adrenocortical carcinoma (part g), advanced solid tumors (part a/b/c/d), high-circulating myeloid-derived suppressor cells (part h), melanoma (part e), mesothelioma (part g), non-small cell lung cancer (part e), squamous cell cancer of the head and neck (part e), triple negative breast cancer (part f)